Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
characteristics of donor and recipient clonal hematopoiesis in nonmyeloablative transplant for sickle cell disease
Original title: “Characteristics of Donor and Recipient Clonal Hematopoiesis in Nonmyeloablative Transplant for Sickle Cell Disease.”
hydromorphone induced choreiform dyskinesia in a patient with homozygous sickle cell disease a reversible adverse effect
Original title: “Hydromorphone-induced choreiform dyskinesia in a patient with homozygous sickle cell disease: a reversible adverse effect.”
orbital compression syndrome mimicking severe malaria in a child with sickle cell disease in a ugandan refugee settlement a case report
Original title: “Orbital Compression Syndrome Mimicking Severe Malaria in a Child with Sickle Cell Disease in a Ugandan Refugee Settlement: A Case Report.”
humanistic and economic burden among caregivers of adults and children with sickle cell disease and recurrent vaso occlusive crises
Original title: “Humanistic and economic burden among caregivers of adults and children with sickle cell disease and recurrent vaso-occlusive crises.”
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
Original title: “Agios scraps sickle cell drug”
Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.
Original title: “Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset”
supportive care prevention and emerging therapies for acute chest syndrome in sickle cell disease
Original title: “Supportive care, prevention, and emerging therapies for acute chest syndrome in sickle cell disease.”